WO2008152655A1 - Anthrax fusion proteins, compositions and uses thereof - Google Patents
Anthrax fusion proteins, compositions and uses thereof Download PDFInfo
- Publication number
- WO2008152655A1 WO2008152655A1 PCT/IN2008/000369 IN2008000369W WO2008152655A1 WO 2008152655 A1 WO2008152655 A1 WO 2008152655A1 IN 2008000369 W IN2008000369 W IN 2008000369W WO 2008152655 A1 WO2008152655 A1 WO 2008152655A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- linker
- anthrax
- recombinant fusion
- fusion proteins
- Prior art date
Links
- 241000193738 Bacillus anthracis Species 0.000 title claims abstract description 148
- 239000000203 mixture Substances 0.000 title claims abstract description 75
- 102000037865 fusion proteins Human genes 0.000 title claims description 43
- 108020001507 fusion proteins Proteins 0.000 title claims description 43
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 136
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 118
- 101710194807 Protective antigen Proteins 0.000 claims abstract description 112
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims abstract description 100
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims abstract description 100
- 206010030113 Oedema Diseases 0.000 claims abstract description 38
- 231100000518 lethal Toxicity 0.000 claims abstract description 35
- 230000001665 lethal effect Effects 0.000 claims abstract description 35
- 238000000034 method Methods 0.000 claims abstract description 33
- 230000008569 process Effects 0.000 claims abstract description 17
- 230000000069 prophylactic effect Effects 0.000 claims abstract description 17
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 11
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 11
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 11
- 230000002163 immunogen Effects 0.000 claims description 40
- 210000004027 cell Anatomy 0.000 claims description 31
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 22
- 208000015181 infectious disease Diseases 0.000 claims description 18
- 239000002671 adjuvant Substances 0.000 claims description 17
- 239000013604 expression vector Substances 0.000 claims description 16
- 241000588724 Escherichia coli Species 0.000 claims description 15
- 239000013612 plasmid Substances 0.000 claims description 15
- 108700012359 toxins Proteins 0.000 claims description 14
- 239000013598 vector Substances 0.000 claims description 12
- 239000004471 Glycine Substances 0.000 claims description 11
- 230000001225 therapeutic effect Effects 0.000 claims description 11
- 230000028993 immune response Effects 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 125000000539 amino acid group Chemical group 0.000 claims description 9
- 229930027917 kanamycin Natural products 0.000 claims description 9
- 229960000318 kanamycin Drugs 0.000 claims description 9
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 9
- 229930182823 kanamycin A Natural products 0.000 claims description 9
- 229940024606 amino acid Drugs 0.000 claims description 8
- 150000001413 amino acids Chemical class 0.000 claims description 8
- 238000011161 development Methods 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 230000029087 digestion Effects 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- 230000008685 targeting Effects 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 4
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims description 4
- NWMHDZMRVUOQGL-CZEIJOLGSA-N almurtide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)CO[C@@H]([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O NWMHDZMRVUOQGL-CZEIJOLGSA-N 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 108010094020 polyglycine Proteins 0.000 claims description 4
- 230000004797 therapeutic response Effects 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 239000006142 Luria-Bertani Agar Substances 0.000 claims description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 229920000232 polyglycine polymer Polymers 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 230000009466 transformation Effects 0.000 claims description 3
- YHQZWWDVLJPRIF-JLHRHDQISA-N (4R)-4-[[(2S,3R)-2-[acetyl-[(3R,4R,5S,6R)-3-amino-4-[(1R)-1-carboxyethoxy]-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]amino]-3-hydroxybutanoyl]amino]-5-amino-5-oxopentanoic acid Chemical compound C(C)(=O)N([C@@H]([C@H](O)C)C(=O)N[C@H](CCC(=O)O)C(N)=O)C1[C@H](N)[C@@H](O[C@@H](C(=O)O)C)[C@H](O)[C@H](O1)CO YHQZWWDVLJPRIF-JLHRHDQISA-N 0.000 claims description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 2
- 229920001817 Agar Polymers 0.000 claims description 2
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 2
- 101100327537 Caenorhabditis elegans cgp-1 gene Proteins 0.000 claims description 2
- 108010039939 Cell Wall Skeleton Proteins 0.000 claims description 2
- 108700015872 N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine Proteins 0.000 claims description 2
- 108700020354 N-acetylmuramyl-threonyl-isoglutamine Proteins 0.000 claims description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 2
- 239000008272 agar Substances 0.000 claims description 2
- 230000003321 amplification Effects 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 210000004520 cell wall skeleton Anatomy 0.000 claims description 2
- 238000012512 characterization method Methods 0.000 claims description 2
- 239000008121 dextrose Substances 0.000 claims description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- JMUHBNWAORSSBD-WKYWBUFDSA-N mifamurtide Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 claims description 2
- 229960005225 mifamurtide Drugs 0.000 claims description 2
- 108700007621 mifamurtide Proteins 0.000 claims description 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims description 2
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 2
- 239000006179 pH buffering agent Substances 0.000 claims description 2
- 108091008146 restriction endonucleases Proteins 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 229940031439 squalene Drugs 0.000 claims description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 2
- 230000001131 transforming effect Effects 0.000 claims description 2
- XETCRXVKJHBPMK-MJSODCSWSA-N trehalose 6,6'-dimycolate Chemical compound C([C@@H]1[C@H]([C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C(CCCCCCCCCCC3C(C3)CCCCCCCCCCCCCCCCCC)C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)O2)O)O1)O)OC(=O)C(C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)CCCCCCCCCCC1CC1CCCCCCCCCCCCCCCCCC XETCRXVKJHBPMK-MJSODCSWSA-N 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 238000009736 wetting Methods 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- 101150077375 LF gene Proteins 0.000 claims 1
- 229960003767 alanine Drugs 0.000 claims 1
- 229940021747 therapeutic vaccine Drugs 0.000 abstract description 4
- 229940021993 prophylactic vaccine Drugs 0.000 abstract description 2
- 235000018102 proteins Nutrition 0.000 description 86
- 229960005486 vaccine Drugs 0.000 description 31
- 230000027455 binding Effects 0.000 description 17
- 108020004414 DNA Proteins 0.000 description 11
- 230000004927 fusion Effects 0.000 description 11
- 239000000443 aerosol Substances 0.000 description 10
- 238000000855 fermentation Methods 0.000 description 10
- 230000004151 fermentation Effects 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 239000003053 toxin Substances 0.000 description 10
- 231100000765 toxin Toxicity 0.000 description 10
- 239000002775 capsule Substances 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 208000022338 anthrax infection Diseases 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 229940065181 bacillus anthracis Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 206010017931 gastrointestinal anthrax Diseases 0.000 description 3
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 229940124899 Biothrax Drugs 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 2
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 101800001707 Spacer peptide Proteins 0.000 description 2
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000009449 inhalation anthrax Diseases 0.000 description 2
- 208000023372 inhalational anthrax Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- 229940097496 nasal spray Drugs 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 210000002268 wool Anatomy 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- KWTQSFXGGICVPE-UHFFFAOYSA-N 2-amino-5-(diaminomethylideneamino)pentanoic acid;hydron;chloride Chemical compound Cl.OC(=O)C(N)CCCN=C(N)N KWTQSFXGGICVPE-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- 208000035742 Air-borne transmission Diseases 0.000 description 1
- 101710092462 Alpha-hemolysin Proteins 0.000 description 1
- 101500000960 Bacillus anthracis Protective antigen PA-63 Proteins 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241001331845 Equus asinus x caballus Species 0.000 description 1
- 241000654838 Exosporium Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 102000004961 Furin Human genes 0.000 description 1
- 108090001126 Furin Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 238000012369 In process control Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 101150105115 PA gene Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010035667 Pneumonia anthrax Diseases 0.000 description 1
- 101710118538 Protease Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000710961 Semliki Forest virus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 230000005557 airborne transmission Effects 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 229940001007 aluminium phosphate Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 229960000754 anthrax vaccine adsorbed Drugs 0.000 description 1
- 229960005447 anthrax vaccines Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000011203 antimicrobial therapy Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 201000004836 cutaneous anthrax Diseases 0.000 description 1
- 238000013400 design of experiment Methods 0.000 description 1
- 238000012444 downstream purification process Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 244000038280 herbivores Species 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000010965 in-process control Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000015286 negative regulation of phagocytosis Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000026447 protein localization Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000010408 sweeping Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 230000007279 water homeostasis Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/07—Bacillus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Definitions
- the present invention relates to anthrax recombinant fusion proteins, process of preparation of such proteins and process for their preparation and composition thereof.
- the recombinant fusion proteins of the present invention comprise an Edema factor protein and
- the present invention further relates to anthrax recombinant fusion proteins comprising Edema factor protein, protective antigen and lethal factor protein optionally with a linker.
- the present invention further relates to the immunogenic composition comprising said anthrax recombinant fusion proteins optionally with the pharmaceutically acceptable adjuvants or excipients or both.
- nucleic acids encoding the fusion proteins of the present invention Further, provided are nucleic acids encoding the DNA construct of the present invention. Further, the present invention relates to process of preparation of anthrax recombinant fusion proteins, compositions comprising said recombinant fusion proteins and methods of using them.
- the compositions of the present invention may be useful as a pre-exposure and post-exposure prophylactic and/or therapeutic vaccine against anthrax.
- Anthrax is an infectious bacterial disease caused by Bacillus anthracis. It occurs most commonly in wild and domestic herbivores (sheep, goats, camels, antelope, cattle, etc.) but may also occur in humans. Infection can occur by cutaneous exposure, by ingestion
- anthrax gastrointestinal anthrax
- pulmonary anthrax 95% of anthrax infections in humans occur by cutaneous infection, either from contact with unvaccinated, infected animals in an agricultural setting, or by handling contaminated animal products (meat, leather, hides, hair, wool, etc.) in an industrial setting. Cutaneous anthrax is fatal in about
- Anthrax vaccine Anthrax Vaccine Adsorbed (or AVA, commercial name BioThrax ® )
- AVA commercial name BioThrax ®
- alum aluminum hydroxide
- the ability of the vaccine to elicit an immune response in humans is well- documented.
- the course of vaccination consists of six subcutaneous injections of 0.5 mL doses of vaccine over eighteen months, with annual boosters to maintain immunity. This vaccination is believed to provide immunity that is 90%- 100% effective against aerosol anthrax challenge, based on animal studies and incidental human data.
- Anthrax a potentially fatal disease, is caused by Bacillus anthracis.
- the virulence of this pathogen is mediated by a capsule of a poly-D- [small gamma, Greek] -glutamic acid and an exotoxin composed of three proteins.
- the three protein components are the protective antigen (PA, 83 KDa), lethal factor (LF, 90.2 KDa) and edema factor (EF, 88.8 KDa) encoded by genes pag, lef, cya respectively in pXOl plasmids.
- PA protective antigen
- LF lethal factor
- EF 88.8 KDa
- LT lethal toxins
- ET edema toxins
- Plasmid pXOl and pXO2 encodes the three toxin components and enzymes for capsule biosynthesis, respectively.
- the genes coding for these three protein components and the capsule are found in the endogenous plasmids pXOl and pXO2, respectively.
- the capsule of Bacillus anthracis composed of poly-D-glutamic acid, serves as one of the principal virulence factors during anthrax infection. By virtue of its negative charge, the capsule is purported to inhibit host defence through inhibition of phagocytosis of the vegetative cells by macrophages.
- the capsule In conjunction with lethal factor (LF) and edema factor (EF), whose target cells include macrophages and neutrophils, respectively, the capsule allows virulent anthrax bacilli to grow virtually unimpeded in the infected host. Spores germinating in the presence of serum and elevated CO[sub]2 release capsule through openings on the spore surface in the form of blebs which may coalesce before sloughing of exosporium and outgrowth of fully encapsulated vegetative cell.
- LF lethal factor
- EF edema factor
- US patent no. 5,591,631 discloses a nucleic acid encoding a fusion protein, comprising a nucleotide sequence encoding the protective antigen (PA) binding domain of the native lethal factor (LF) protein and a nucleotide sequence encoding a polypeptide, wherein said fusion protein lacks the catalytic domain of LF.
- PA protective antigen
- LF native lethal factor
- US patent no. 5,677,274 describes a method for targeting compounds having a desired biological activity not present on native anthrax lethal factor (LF) to a specific cell population, comprising: a) administering to the cell population a first compound comprising a first protein consisting essentially of: i) the translocation domain and the anthrax lethal factor (LF) binding domain of the native anthrax protective antigen (PA) protein, and ii) a ligand domain that specifically binds the first protein to a target on the surface of the cell population to bind the first compound to said surface; and b) administering to the resultant cell population a second compound comprising a fusion protein or conjugate consisting essentially of: i) the anthrax protective antigen (PA) binding domain of the native anthrax lethal factor (LF) protein, chemically attached to ii) a biological activity-inducing polypeptide to bind the second compound to the first compound on the surface of the cell population, internalize the second compound into the cell population, and
- US publication no. 20040028695 describes an immunogenic composition to prepare a vaccine against a lethal infection of B. anthracis in an animal comprising an effective immunizing amount of at least one recombinant B. anthracis PA (rPA) protein and at least one recombinant B. anthracis LF (rLF) protein.
- rPA B. anthracis PA
- rLF recombinant B. anthracis LF
- PCT publication no. WO2003048390 describes a recombinant DNA Construct comprising an expression vector and a DNA fragment including genes for wild type Protective Antigen (PA) or wild type Lethal Factor (LF) or wild type Edema Factor (EF).
- PA Protective Antigen
- LF wild type Lethal Factor
- EF Edema Factor
- PCT publication no. WO2003040179 discloses a process for preparing anthrax protective antigen protein from E.coli using fed batch culture technique.
- PCT publication no. WO200337370 discloses an antigenic pharmaceutical composition
- an antigenic pharmaceutical composition comprising Protective Antigen (PA) and Lethal Factor (LF), wherein said PA and/or LF lacks a functional binding site, thereby preventing said PA and LF from binding together via said binding site or thereby preventing said PA from binding to a native PA cell receptor via said binding site, and wherein said composition is substantially non-toxic to animal cells.
- PA Protective Antigen
- LF Lethal Factor
- PCT publication no. WO2002100340 describes an immunogenic composition capable of raising an an ⁇ -B. anthracis antigen immune response in a mammal consisting essentially of recombinant B. anthracis Protective Antigen (rPA).
- rPA anthracis Protective Antigen
- the present invention not only provides a cost-effective method to develop safe and effective vaccine against anthrax but also attempts to provide a single vaccine composition that may be useful both as a pre-exposure and post-exposure prophylactic and/or as a therapeutic product.
- anthrax recombinant fusion proteins comprising a native or mutated or truncated Edema factor protein, a native or mutated or truncated Lethal factor protein and a native or mutated or mature PA wherein the LFn acts as a linker optionally with one or more other linker(s).
- anthrax recombinant fusion proteins comprising truncated Edema factor protein (SEQ. ID No. 2), and protective antigen optionally with a linker wherein linker is truncated lethal factor protein (SEQ. ID No. 1)
- anthrax recombinant fusion proteins comprising EFn protein, LFn protein and a native or mutated or mature PA wherein the LFn protein acts as a linker optionally with one or more other linker(s).
- an immunogenic composition against an infection of B. anthracis which comprises an anthrax recombinant fusion protein comprising a EFn protein and a native or mutated or mature PA optionally with a linker, and optionally with one or more suitable adjuvant(s).
- an immunogenic composition against an infection of B. anthracis which comprises a mixture of an anthrax recombinant fusion protein comprising a EFn protein and a native or mutated or mature PA optionally with a linker, and a truncated anthrax recombinant protein preferably LFn, optionally with one or more suitable adjuvant(s).
- It is a further objective of the present invention to provide a composition comprising anthrax recombinant fusion protein along with EFn protein and/or LFn protein.
- composition comprising anthrax recombinant fusion protein along with a recombinant fusion protein comprising EFn protein and LFn protein optionally with one or more other linker(s).
- an immunogenic composition comprising anthrax recombinant fusion proteins comprising truncated Edema factor protein (SEQ. ID No. 2), and protective antigen optionally with a linker wherein linker is truncated lethal factor protein (SEQ. ID No. 1)
- an immunogenic composition comprising anthrax recombinant fusion proteins comprising truncated Edema factor protein (SEQ. ID No. 2), lethal factor protein (SEQ. ID No. 1) and protective antigen optionally with a linker.
- an immunogenic composition comprising anthrax recombinant fusion protein selected from amino acid sequence set forth in SEQ ID No. 3 or SEQ ID No. 4 or SEQ ID No. 5 optionally with one or more pharmaceutically acceptable adjuvants 10
- compositions which are potentially immunogenic and safe.
- compositions are useful as a prophylactic and/or a therapeutic vaccine against anthrax.
- the present invention thus provides a method of producing an immunogenic prophylactic or therapeutic response against an infection of B. anthracis in a mammal comprising the step of administering to a mammal the immunogenic composition of the present invention described herewith.
- FIG. 2 Schematic representation of recombinant expression plasmid "pPAK- NATPRO"
- Figure-3 shows a codon optimized Sequence of PA.
- Figure-4 shows a Protein Sequence of PA.
- Figure-5 shows a LFn with Glycine as linker Recombinant Construct in pET28a, wherein clone LFn has been constructed for the expression of LFn in E.coli BL21(DE3).
- the genes were amplified from the pXOl region of the B. anthracis using specific primers and inserted in pET-28a expression vector having Kanamycin as selection marker.
- the recombinant plasmid was then transformed into E.coli BL21 (DE3) cells for the expression of protein.
- Figure-6 shows a Nucleotide Sequence of truncated LF.
- Figure 7 shows a Protein Sequence of truncated LF (SEQ. ID No. 1).
- Figure-8 SDS-PAGE analysis of rLFn expression
- Figure-9 shows an EFn Recombinant Construct in pET28a, wherein clone EFn has been constructed for the expression of LFn in E.coli BL21(DE3).
- the genes were amplified from the pXO 1 region of the B. anthracis using specific primers and inserted in pET-28a expression vector having Kanamycin as selection marker.
- the recombinant plasmid was then transformed into E.coli BL21 (DE3) cells for the expression of protein
- Figure-10 shows a Nucleotide Sequence of truncated EF.
- Figure-11 shows a Protein Sequence of truncated EF (SEQ. ID No. 2)
- Figure- 13 shows an EFn+PA with LFn as linker Fusion Construct in pET28a, wherein recombinant fusion construct of EFn+PA fusion protein has been developed using LFn as the linker gene.
- the genes were amplified from the pXOl region of the B. anthracis using specific primers and inserted in pET-28a expression vector having Kanamycin as selection marker.
- the recombinant plasmid was then transformed into E.coli BL21 (DE3) cells for the expression of fusion protein.
- Figure- 14 shows an EFn+PA with LFn as linker Fusion Construct (SEQ. ID No. 3)
- Figure- 15 shows the Primers for EFn, LFn and PA in Recombinant Construct EFn+PA with LFn as linker in pET28a.
- Figure- 16 shows an EFn+PA with LFn and Glycine as linker Fusion Construct in pET28a, wherein recombinant fusion construct of EFn+PA fusion protein has been developed using LFn and poly-glycine gene as linkers.
- the EFn, PA and LFn genes were amplified from the pXOl region of the B. anthracis using specific primers. Primers were designed to insert the polyglycine residues between each gene.
- pET-28a expression vector with Kanamycin as selection marker was used for cloning of the fusion protein. Transformation was done in E.coli BL21 (DE3) cells for the expression of fusion protein.
- Figure- 17 shows an EFn+PA with LFn and Glycine as linker Fusion Construct (SEQ. ID No. 4)
- Figure- 18 shows the Primers for EFn+PA with LFn and Glycine as linker Fusion Construct.
- Figure- 19 shows an EFn+PA with Glycine as linker Fusion Construct in pET28a, wherein recombinant fusion construct of EFn+PA fusion protein has been developed.
- the gene for EFn and PA was amplified from pXOl plasmid of B. anthracis using specific primers and was inserted in pET-28a expression vector having Kanamycin as selection marker. The recombinant plasmid was then transformed into E.coli BL21 (DE3) cells for the expression of fusion protein.
- Figure-20 shows an EFn+PA with Glycine as linker Fusion Construct (SEQ. ID No. 5).
- the present invention provides anthrax recombinant fusion proteins and nucleic acids encoding the anthrax recombinant fusion proteins.
- the present invention provides anthrax recombinant fusion proteins comprising a native or mutated or truncated Edema factor protein preferably a truncated Edema factor protein and a native or mutated or mature Protective Antigen optionally with a linker.
- the present invention provides an anthrax recombinant fusion protein comprising a native or mutated or truncated EF protein preferably a EFn, a native or mutated or truncated LF protein preferably a truncated Lethal factor protein and a native or mutated or mature PA wherein the LFn acts as a linker optionally with one or more other linker(s) such as one or more amino acid residues.
- the anthrax recombinant fusion protein or a combination of such fusion protein preferably with a truncated anthrax recombinant protein can result in faster immune responses by targeting all three toxin proteins.
- PA Protective Antigen
- LF Lethal Factor
- EF Esdema Factor
- the present invention provides an immunogenic composition against an infection of B. anthracis which comprises a mixture of an anthrax recombinant fusion protein comprising EFn protein and a native or mutated or mature PA optionally with a linker, and a truncated anthrax recombinant protein preferably LFn, optionally with one or more suitable adjuvant(s).
- the present invention provides a pre-exposure and postexposure prophylactic and/or a therapeutic composition useful against an infection of B.
- anthracis in a subject which comprises administration of an effective amount of an anthrax recombinant fusion protein comprising EFn protein and a native or mutated or mature PA optionally with a truncated anthrax recombinant protein preferably LFn, and optionally one or more adjuvant(s) to the said subject.
- the present invention also provides a DNA construct comprising an expression vector and a DNA fragment comprising nucleic acids encoding the anthrax recombinant fusion protein such that the expression vector when incorporated into a suitable host allows expression of an anthrax recombinant fusion protein.
- a vaccine composition which is potentially immunogenic and safe. Particularly the compositions are useful as a pre-exposure and post-exposure prophylactic and/or a therapeutic vaccine against anthrax.
- the anthrax recombinant fusion protein comprises EFn and a mature Protective Antigen optionally with a linker.
- a mature PA also referred to as PA 83 is one wherein there is a cleavage of 29 amino acid residues signal sequence from the native PA. In this state, the PA is inactive except for its binding affinity for a receptor. Only after the furin-mediated cleavage to form PA 63 , the binding of one of the other toxin components is possible. Heptamerization and pore formation after acidification leads to a structure similar to the staphylococcal alpha- hemolysin. Use of a mutated PA also prevents the binding of the Edema factor protein or Lethal factor protein and thus might avoid the formation of Edema Toxin or Lethal Toxin respectively leading to better product safety.
- the composition of the present invention comprising anthrax recombinant fusion protein is capable of producing at least one or more of the anti-PA and anti-EF antibodies that shall work as neutralizing molecules and, therefore, shall interrupt binding activities of the anthrax toxin.
- the LF and the EF protein share high N-terminal amino acid homology, some of the antibodies raised against the N-terminal of EF will also react with LF. Therefore, the present invention, by using EFn and native or mutated or mature PA as antigens, may result in faster immune responses by targeting all three toxin proteins since the presence of different antibodies allows attack of different proteins at the same time.
- EFn and LFn provides competitive binding to wild type EF and LF and hence provides more therapeutic protection.
- the action of the vaccine of the present invention will be more effective in the post exposure therapeutic cases, as the EFn protein given during the vaccination process will also compete with natural EF or LF for the binding with the site of natural/wild type PA associated with the bacterial infection.
- the wild type PA when bound to the EFn will not produce any toxic effect and thus help in providing a potent therapeutic product against the bioterrorist attack or accidental spread of Anthrax spores.
- an anthrax recombinant fusion protein comprising EFn protein and a native or mutated or mature PA optionally with a linker is provided to target all three proteins i.e., PA, LF, and EF.
- Many of the antibodies produced against EFn or LFn may neutralize the toxic effect of the anthrax toxin by interrupting the binding of EF and/or LF with PA.
- the present invention provides an anthrax recombinant fusion protein comprising a native or truncated EF protein, a native or truncated LF protein and a native or mutated or mature PA optionally with one or more linkers inserted at one or more sites of the fusion protein chain.
- the linker is selected from a group comprising a Lethal factor (LF), a region of LF and amino acids such as glycine, polyglycine or combinations thereof or amino acid residues.
- LF Lethal factor
- the linker is also herein referred to as a spacer peptide.
- the present invention provides an anthrax recombinant fusion protein comprising truncated Edema factor protein (SEQ. ID No. 2) and protective antigen optionally with linker wherein linker is truncated lethal factor protein (SEQ. ID No. 1)
- the present invention provides an anthrax recombinant fusion protein comprising truncated Edema factor protein (SEQ. ID No. 2), truncated lethal factor protein (SEQ. ID No. 1) and protective antigen optionally with a linker.
- the present invention provides an anthrax recombinant fusion protein comprising truncated Edema factor protein (SEQ. ID No. 2) and protective antigen optionally with linker wherein linker is amino acid or amino acid residue such as glycine.
- the present invention provides an immunogenic composition
- anthrax recombinant fusion protein comprising truncated Edema factor protein (SEQ. ID No. 2) and protective antigen optionally with linker wherein linker is truncated lethal factor protein (SEQ. ID No. 1).
- the present invention provides an immunogenic composition comprising anthrax recombinant fusion protein (SEQ. ID. No. 3)
- the present invention provides an immunogenic composition
- anthrax recombinant fusion protein comprising truncated Edema factor protein (SEQ. ID No. 2), truncated lethal factor protein (SEQ. ID No. 1) and protective antigen optionally with a linker.
- the present invention provides an immunogenic composition comprising anthrax recombinant fusion protein (SEQ. ID. No. 4)
- the present invention provides an immunogenic composition
- anthrax recombinant fusion protein comprising truncated Edema factor protein (SEQ. ID No. 2) and protective antigen optionally with linker wherein linker is amino acid or amino acid residue such as glycine.
- the present invention provides an immunogenic composition comprising anthrax recombinant fusion protein (SEQ. ID. No. 5)
- the present invention provides an anthrax recombinant fusion protein that eases the vaccine production by reducing the need for at least three separate production lines for fermentation and purification procedures for each protein i.e. PA, EFn and LFn individually.
- PA protein
- EFn protein
- LFn truncated anthrax recombinant protein
- Both the EFn-PA fusion protein and the LFn protein can then be mixed in order to obtain the desired vaccine composition of present invention.
- the anthrax recombinant fusion proteins of the present invention are designed in a particular sequence so as to produce a high yield of the proteins.
- the anthrax recombinant fusion proteins comprise of sequence comprising EFn linked with native or mutated or mature PA by the linker LFn, wherein the EFn and the LFn, and LFn and the native or mutated or mature PA are linked with glycine residue(s).
- the said particular sequence is surprisingly found to be highly expressive thus leading to a high yield.
- the said particular sequence of the anthrax proteins improves the immunogenic and/or therapeutic properties and/or the safety profile of the vaccine made by using the novel fusion proteins of the present invention.
- At least two antigenic B. anthracis proteins are expressed as a fusion protein, in an E. coli host cell such as the BL- 21(DE3) (from Novagen).
- the expressed proteins are produced by an optimized fermentation method and purified by one or more techniques known to the art such as column chromatography.
- the purified proteins are useful in formulating an immunogenic composition, which is again useful as a vaccine against infections caused by B. anthracis.
- Development of an E. coli BL-21(DE3) expression system involves the development of expression vector (plasmids) to express the target recombinant fusion proteins in an E. coli BL-21(DE3). It might however be understood that alternative vectors/plasmids and/or expression host might be utilized for the production of the novel fusion proteins of the present invention such as the use of Bacillus subtilis as the host cell for the fusion protein expression.
- the expression vector described herein is for use in a prokaryotic system; the vector also can contain elements required for replication in either a prokaryotic or eukaryotic host system or both, as desired.
- vectors which include plasmid vectors and viral vectors such as bacteriophage, baculovirus, retrovirus, lentivirus, adenovirus, vaccinia virus, semliki forest virus and adeno-associated virus vectors, are well known and can be purchased from a commercial source (Promega, Madison Wis.; Stratagene, La Jolla Calif.; GIBCO/BRL, Gaithersburg Md.) or can be constructed by one skilled in the art.
- Bacterial pQE70, pQE30, pET28a (Qiagen), pBluescript SK, pBluescript KS (Stratagene); pTRC99a, pRlT2T (Pharmacia); Eukaryotic: pWLNEO, pXTI, pSG (Stratagene) pSVK3, pSVLSV40 (Pharmacia). Any. other plasmid or vector may be used as long as they are replicable and viable in the host being used to express the fusion proteins of the present invention.
- a process for preparation of anthrax recombinant fusion proteins comprises the following steps:
- step (3) optionally mixing these fusion proteins and adding one or more suitable adjuvant(s) to step (3) or step (4).
- the process for preparation of an anthrax recombinant fusion protein comprises the following steps: 1. Amplification of the PA and EFn and optionally LFn gerie from the genomic DNA of Bacillus antharacis using specific primers optionally having glycine residues as linker,
- the method used for the preparation of fusion proteins is selected from one of more methods known to the art.
- the upstream process for an anthrax recombinant fusion protein production may be carried out by a batch process or preferably by using fed-batch culture technique to improve the yield of the fusion protein.
- the optimization of various fermentation parameters using fed-batch conditions shall improve protein yields and stability. Standardization of fermentation parameters shall require systematic design of experiments as follows: a) Different nitrogen source such as Soya peptone, yeast extract, yeast autolysate, corn steep liquor or the like or mixtures thereof in the fermentation media. b) Different carbon sources such as glucose, glycerol, galactose, maltose, fructose, lactose or the like or mixtures thereof in the fermentation media.
- the fermentation media used in the present invention is devoid of any component obtained from an animal source.
- the downstream purification process of the recombinant fusion proteins is based upon their localization in the cell as inclusion bodies, periplasmic fluid or extracellular secretions. Based on the nature of protein localization and its isoelectric point (PI), various chromatographic methods may be used such as anion exchange chromatography, hydrophobic interaction chromatography and size exclusion or gel filtration chromatography, difiltration or the like, or combinations thereof.
- PI isoelectric point
- an anthrax recombinant fusion protein shall work as neutralizing molecules and, therefore, will interrupt binding activities of the anthrax toxins with each other.
- PA is a 735-amino acid polypeptide of about 83 kDa that binds to the surface of mammalian cells by cellular receptors. Once bound, PA is activated by proteolytic cleavage by cellular proteases to a 63-kDa and 20-kDa molecule.
- 63-kDa molecule is capable of forming a ring-shaped heptamer in the plasma membrane of the targeted cell exposing PA binding sites for the N-terminal region of either LF or EF which are then internalized by endocytosis.
- the complex is then carried to an acidic compartment, where the low pH causes a conformational change in the PA63 pre-pore that forms a cation-specific channel and allows the EF and LF to enter into the cytosol. This process is known as endosomal acidification.
- the EF and LF then carry out their respective damage- inducing processes.
- EF acts as a Ca2+ and calmodulin dependent adenylate cyclase that greatly increases the level of cAMP in the cell. This increase in cAMP upsets water homeostasis, severely throws the intracellular signaling pathways off balance, and impairs macrophage function, allowing the bacteria to further evade the immune system. LF also helps the bacteria evade the immune system through killing macrophages. Once in these cells, LF acts as a Zn 2+ -dependent endoprotease that snips off the N-terminus of mitogen-activated protein kinase kinases (MAPKK).
- MAPKK mitogen-activated protein kinase kinases
- PA is the major immunogen in the anthrax vaccines.
- Antibodies to PA neutralize anthrax toxin by blocking adherence of PA to host cells, binding of LF/EF to PA, or assembly of PA heptamer.
- LF represents both a prophylactic and therapeutic target because it has been reported to play a vital role at two different points in anthrax infection. It elicits humoral and cell-mediated immune response and memory.
- an immunogenic composition to prepare a vaccine against an infection of B. anthracis in a subject and includes an effective immunizing amount of a recombinant fusion protein comprising EFn protein and a native PA optionally with a linker.
- the vaccine may be administered by conventional routes, e.g. intravenous, subcutaneous, intraperitoneal and mucosal routes.
- the said vaccine can be administered through jet injection with needle or without needle.
- such vaccines are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior to injection may also be prepared.
- the preparation may also be emulsified, or the peptide encapsulated in liposomes or microcapsules.
- the active immunogenic ingredients are often mixed with excipients which are pharmaceutically acceptable and compatible with the active components. Suitable excipients are for example, water, saline, dextrose, glycerol, ethanol, sugars or the like and combinations or derivatives thereof.
- the vaccine may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and/or adjuvants which enhance the effectiveness of the vaccine.
- adjuvants which may be effective include but are not limited to aluminum hydroxide, aluminium phosphate, calcium phosphate, immunostimulatory sequence (ISS), CpG, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP),, N-acetyl-nor- muramyl-L-alanyl-D-isoglutamine (CGP 1 1637, referred to as nor-MDP), N- acetylmuramyl-L-alanyl-D-isoglutaminyl -L -alanine (1 '-2'-dipalmitoyl-sn-glycero hydroxylphosphoryloxy) ethylamine (CGP 19835 A, referred to as MTP-PE
- the vaccines of the present invention may be conventionally administered parenterally by injection, for example, either subcutaneously or intramuscularly.
- the vaccines are administered in a manner compatible with the dosage formulation, and in such amount as will be prophylactically and/or therapeutically effective.
- the quantity to be administered which is generally in the range of 0.5 micrograms to 500 micrograms of protein per dose, depends on the subject to be treated, capacity of the subject's immune system to synthesize antibodies, and the degree of protection desired. Precise amounts of active ingredient required to be administered may depend on the judgment of the practitioner and may be particular to each subject.
- the vaccine may be given in a single dose schedule, or optionally in a multiple .dose schedule.
- a multiple dose schedule is one in which, a primary course of vaccination may be with 1-12 preferably 1-6 separate doses, followed by other doses given at subsequent time intervals required to maintain and/or reinforce the immune response, for example, at 1 -4 months for a second dose, and if needed, a subsequent dose(s) after several months.
- the dosage regimen will also at least in part be determined by the need of the individual and be dependent upon the judgment of the practitioner.
- the vaccine containing the immunogenic antigen(s) may be administered in conjunction with other immunoregulatory agents, for example, immunoglobulins, as well as antibiotics.
- Additional formulations which are suitable for other modes of administration include microcapsules, suppositories and, in some cases, oral formulations or formulations suitable for distribution as aerosols.
- traditional binders and carriers may include, for example, polyalkylene glycols or triglycerides; such suppositories may be formed from mixtures containing the active ingredient in the range of 0.5 % to 10 %, preferably 1 -2%.
- Oral formulations include such normally employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate and the like. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and contain 10%-95% of active ingredient, preferably 25%-70%.
- the medicament may be administered intranasally (i.n.).
- An intranasal composition may be administered in droplet form having approximate diameters in the range of 10-5000 pm. Intranasal administration may be achieved by way of applying nasal droplets or via a nasal spray. It is possible that, following intranasal delivery of antibodies, their passage to the lungs may facilitated by a reverse flow of mucosal secretions.
- the medicament may be delivered in an aerosol formulation.
- the aerosol formulation may take the form of a powder, suspension or solution.
- the size of aerosol particles is one factor relevant to the delivery capability of an aerosol. Thus, smaller particles may travel further down the respiratory airway towards the alveoli than would larger particles.
- the aerosol particles have a diameter distribution to facilitate delivery along the entire length of the bronchi, bronchioles, and alveoli.
- the particle size distribution may be selected to target an articular section of the respiratory airway, for example the alveoli.
- the aerosol particles may be delivered by way of a nebulizer or nasal spray.
- the particles may have diameters in the approximate range of 0-50 pm, preferably 1-5 pm.
- the aerosol formulation of the medicament of the present invention may optionally contain a propellant and/or surfactant.
- a propellant and/or surfactant By controlling size of droplets which are to be administered to a subject to within the defined range of the present invention, it is possible to avoid/minimise inadvertent antigen delivery to the alveoli and thus avoid alveoli associated pathological problems such as inflammation and fibrotic scarring of the lungs.
- the fusion proteins or compositions comprising such proteins may be delivered as topical/transdermal formulation e.g. skin delivery patches.
- a method to produce an immunogenic prophylactic or therapeutic response against an infection of B. anthracis in a subject which comprises administration of an effective amount of an anthrax recombinant fusion protein comprising EFn protein, a native or mutated or mature PA and a linker which is LFn protein and/or one or more other amino acid residues, and optionally one or more adjuvant(s) to the said subject.
- a subject as used herein, is a mammal, particularly domesticated livestock, animals including but not limited to dogs, cats, cows, bulls, steers, pigs, horses, sheep, goats, mules, donkeys, etc and humans.
- the subject is a human.
- a subject can be of any age at which the subject is able to respond to inoculation with the present vaccine by generating an immune response.
- the immune response so generated can be completely or partially protective against disease, cellular toxicity, debilitation or death caused by infection with B. anthracis.
- a subject is also one to which a composition comprising the recombinant fusion proteins of the present invention can be administered prophylactically and/or therapeutically.
- PA Protective antigen (PA) gene has been codon optimized and synthesized for protein product expression in E.coli.
- Commercial vector pET 26b (+) were used to express PA gene. After restriction digestion of the gene and vector, both were ligated and transformed into TOPlO ⁇ E.coli) competent cells. The transformanfs were plated on LB agar containing 50 ⁇ g/ml kanamycin. The colonies on the plates were screened by colony PCR for the presence of the desired gene. The selected clone was confirmed by restriction mapping and sequencing. The recombinant construct was then transformed into E.coli BL21 (DE3) cells for the expression of protein.
- Below fig-1 illustrate the schematic representation of expression system. The expressed protein was confirmed for its size on SDS-PAGE gel and also by western blotting using Anti-PA monoclonal antibody available from US Biologicals.
- Recombinant fusion construct EFn-LFn-PA fusion protein was developed using PA, EFn and LFn gene amplified from Bacillus anthracis using specific primers having glycine residues as spacer peptide inserted in pET-28a expression vector which has Kanamycin as selection marker. The recombinant plasmid was then transformed into E.coli BL21 (DE3) cells for the expression of fusion protein.
- immunogenic composition of anthrax recombinant fusion proteins of the present invention can prepared by following process:
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention relates to anthrax recombinant fusion proteins, process of preparation of such proteins and compositions thereof. Particularly the recombinant fusion proteins of the present invention comprise a native Edema factor protein (EF) or mutated Edema factor protein (EFm) or truncated Edema factor protein (EFn) and a native or mutated or mature Protective Antigen (PA) optionally with a linker wherein the linker is optionally a native Lethal factor protein (LF) or mutated Lethal factor protein (LFm) or truncated Lethal factor protein (LFn). Further, provided are nucleic acids encoding the DNA construct of the present invention. The compositions of the present invention may be useful as a pre-exposure and post-exposure prophylactic and/or therapeutic vaccine against anthrax.
Description
ANTHRAX FUSION PROTEINS, COMPOSITIONS AND USES THEREOF
FIELD OF THE INVENTION
The present invention relates to anthrax recombinant fusion proteins, process of preparation of such proteins and process for their preparation and composition thereof. Particularly the recombinant fusion proteins of the present invention comprise an Edema factor protein and
''' Protective Antigen (PA) optionally with a linker. The present invention further relates to anthrax recombinant fusion proteins comprising Edema factor protein, protective antigen and lethal factor protein optionally with a linker. The present invention further relates to the immunogenic composition comprising said anthrax recombinant fusion proteins optionally with the pharmaceutically acceptable adjuvants or excipients or both. Also provided are nucleic acids encoding the fusion proteins of the present invention. Further, provided are nucleic acids encoding the DNA construct of the present invention. Further, the present invention relates to process of preparation of anthrax recombinant fusion proteins, compositions comprising said recombinant fusion proteins and methods of using them. The compositions of the present invention may be useful as a pre-exposure and post-exposure prophylactic and/or therapeutic vaccine against anthrax.
BACKGROUND OF THE INVENTION
Anthrax is an infectious bacterial disease caused by Bacillus anthracis. It occurs most commonly in wild and domestic herbivores (sheep, goats, camels, antelope, cattle, etc.) but may also occur in humans. Infection can occur by cutaneous exposure, by ingestion
(gastrointestinal anthrax), or by inhalation (pulmonary anthrax). 95% of anthrax infections in humans occur by cutaneous infection, either from contact with unvaccinated, infected animals in an agricultural setting, or by handling contaminated animal products (meat, leather, hides, hair, wool, etc.) in an industrial setting. Cutaneous anthrax is fatal in about
20% of cases if untreated, but it can usually be overcome with appropriate antimicrobial therapy. Inhalation or gastrointestinal anthrax infection is much more serious and much more difficult to treat. Inhalation anthrax results in respiratory shock and is fatal in 90%-
100% of cases; gastrointestinal anthrax results in severe fever, nausea and vomiting, resulting in death in 25%-75% of cases. An effective vaccine against pre-exposure prophylactic to anthrax was developed in United States in the 1950s and 1960s, and a vaccine was approved by FDA in 1970.
In recent years the threat of air borne transmission of anthrax has been thought to increase as B. anthracis was identified as a possible agent for biological warfare. This threat has now been realized in the past year in the form of mailed anthrax spores, resulting in several deaths in the US. Whereas historically only individuals at high risk, such as veterinarians, livestock handlers, wool shearers, abattoir workers, etc. were needed to consider being vaccinated, the threat to military personnel of the possibility of biological weapons deployment caused the United States military to adopt a sweeping anthrax vaccination program in 1997, under which it was intended to administer the anthrax vaccine to 2.4
million military personnel in all branches of service. The most effective known method for preventing anthrax is vaccination. The only mass produced anthrax vaccine, Anthrax Vaccine Adsorbed (or AVA, commercial name BioThrax®), is a noninfectious sterile filtrate of an attenuated V770-NP1-R strain of B. anthracis, adsorbed to aluminum hydroxide (alum) adjuvant, with <0.02% formaldehyde and 0.0025% benzethonium chloride added. The ability of the vaccine to elicit an immune response in humans is well- documented. The course of vaccination consists of six subcutaneous injections of 0.5 mL doses of vaccine over eighteen months, with annual boosters to maintain immunity. This vaccination is believed to provide immunity that is 90%- 100% effective against aerosol anthrax challenge, based on animal studies and incidental human data.
Anthrax, a potentially fatal disease, is caused by Bacillus anthracis. The virulence of this pathogen is mediated by a capsule of a poly-D- [small gamma, Greek] -glutamic acid and an exotoxin composed of three proteins. The three protein components are the protective antigen (PA, 83 KDa), lethal factor (LF, 90.2 KDa) and edema factor (EF, 88.8 KDa) encoded by genes pag, lef, cya respectively in pXOl plasmids. These proteins, non-toxic by themselves, form lethal toxins (LT) and edema toxins (ET) when combined with an activated PA. Plasmid pXOl and pXO2 encodes the three toxin components and enzymes for capsule biosynthesis, respectively. The genes coding for these three protein components and the capsule are found in the endogenous plasmids pXOl and pXO2, respectively. The capsule of Bacillus anthracis, composed of poly-D-glutamic acid, serves as one of the principal virulence factors during anthrax infection. By virtue of its negative charge, the capsule is purported to inhibit host defence through inhibition of phagocytosis of the vegetative cells by macrophages. In conjunction with lethal factor (LF) and edema factor (EF), whose target cells include macrophages and neutrophils, respectively, the capsule allows virulent anthrax bacilli to grow virtually unimpeded in the infected host. Spores germinating in the presence of serum and elevated CO[sub]2 release capsule through openings on the spore surface in the form of blebs which may coalesce before sloughing of exosporium and outgrowth of fully encapsulated vegetative cell.
US patent no. 5,591,631 discloses a nucleic acid encoding a fusion protein, comprising a nucleotide sequence encoding the protective antigen (PA) binding domain of the native lethal factor (LF) protein and a nucleotide sequence encoding a polypeptide, wherein said fusion protein lacks the catalytic domain of LF.
US patent no. 5,677,274 describes a method for targeting compounds having a desired biological activity not present on native anthrax lethal factor (LF) to a specific cell population, comprising: a) administering to the cell population a first compound comprising a first protein consisting essentially of: i) the translocation domain and the anthrax lethal factor (LF) binding domain of the native anthrax protective antigen (PA) protein, and ii) a ligand domain that specifically binds the first protein to a target on the
surface of the cell population to bind the first compound to said surface; and b) administering to the resultant cell population a second compound comprising a fusion protein or conjugate consisting essentially of: i) the anthrax protective antigen (PA) binding domain of the native anthrax lethal factor (LF) protein, chemically attached to ii) a biological activity-inducing polypeptide to bind the second compound to the first compound on the surface of the cell population, internalize the second compound into the cell population, and effect the activity of the polypeptide therein.
US publication no. 20040028695 describes an immunogenic composition to prepare a vaccine against a lethal infection of B. anthracis in an animal comprising an effective immunizing amount of at least one recombinant B. anthracis PA (rPA) protein and at least one recombinant B. anthracis LF (rLF) protein.
PCT publication no. WO2003048390 describes a recombinant DNA Construct comprising an expression vector and a DNA fragment including genes for wild type Protective Antigen (PA) or wild type Lethal Factor (LF) or wild type Edema Factor (EF).
PCT publication no. WO2003040179 discloses a process for preparing anthrax protective antigen protein from E.coli using fed batch culture technique.
PCT publication no. WO200337370 discloses an antigenic pharmaceutical composition comprising Protective Antigen (PA) and Lethal Factor (LF), wherein said PA and/or LF lacks a functional binding site, thereby preventing said PA and LF from binding together via said binding site or thereby preventing said PA from binding to a native PA cell receptor via said binding site, and wherein said composition is substantially non-toxic to animal cells.
PCT publication no. WO2002100340 describes an immunogenic composition capable of raising an anύ-B. anthracis antigen immune response in a mammal consisting essentially of recombinant B. anthracis Protective Antigen (rPA).
Most of the prior art vaccines either compromise on efficacy or on safety, for example the BioThrax® vaccine is known to possess high incidence of side effects, and other vaccines which comprise mutagenized PA are comparatively less immunogenic than the native or mature PA. Further, no vaccine is reported in the prior art which can be used both as a pre-exposure and post-exposure prophylactic for the treatment of anthrax infection. Hence there still exists a need to develop new vaccine compositions against anthrax infection which are safe and effective and which preferably can be used as a pre-exposure and post-exposure prophylactic and/or therapeutic.
Further there still exists a need to develop two or more anthrax proteins selected from PA, EF and LF in such a manner so that the same can be obtained by a single or at the most two separate production lines for fermentation and purification procedures.
The present invention not only provides a cost-effective method to develop safe and effective vaccine against anthrax but also attempts to provide a single vaccine composition that may be useful both as a pre-exposure and post-exposure prophylactic and/or as a therapeutic product.
SUMMARY OF THE INVENTION
It is an objective of the present invention to provide the anthrax recombinant fusion proteins and process for the preparation thereof.
It is also an objective of the present invention to provide anthrax recombinant fusion proteins comprising Edema factor protein and protective antigen optionally with a linker.
It is also an objective of the present invention to provide nucleic acids encoding the anthrax recombinant fusion proteins.
It is a further objective of the present invention to provide anthrax recombinant fusion proteins comprising a native or mutated or truncated Edema factor protein and a native or mutated or mature Protective Antigen optionally with a linker.
It is a further objective of the present invention to provide anthrax recombinant fusion proteins comprising a truncated Edema factor protein and a native or mutated or mature Protective Antigen optionally with a linker.
It is a further objective of the present invention to provide anthrax recombinant fusion proteins comprising a native or mutated or truncated Edema factor protein, a native or mutated or truncated Lethal factor protein and a native or mutated or mature PA wherein the LFn acts as a linker optionally with one or more other linker(s).
It is a further objective of the present invention to provide anthrax recombinant fusion proteins comprising truncated Edema factor protein (SEQ. ID No. 2), and protective antigen optionally with a linker wherein linker is truncated lethal factor protein (SEQ. ID No. 1)
It is a further objective of the present invention to provide anthrax recombinant fusion
proteins comprising EFn protein, LFn protein and a native or mutated or mature PA wherein the LFn protein acts as a linker optionally with one or more other linker(s).
It is another objective of the present invention to provide anthrax recombinant fusion proteins comprising truncated Edema factor protein (SEQ. ID No. 2), lethal factor protein (SEQ. ID No. 1) and protective antigen optionally with a linker.
It is another objective of the present invention to provide anthrax recombinant fusion proteins or a combination of such fusion proteins preferably with a truncated anthrax recombinant protein which can result in faster prophylactic and therapeutic immune responses immune responses, including both pre-exposure and post-exposure, by targeting all three toxin proteins namely PA, EF and LF.
It is another objective of the present invention to provide process for preparation of anthrax recombinant fusion proteins.
It is further an objective of the present invention to provide an immunogenic composition against an infection of B. anthracis which comprises an anthrax recombinant fusion protein comprising a EFn protein and a native or mutated or mature PA optionally with a linker, and optionally with one or more suitable adjuvant(s).
It is further an objective of the present invention to provide an immunogenic composition against an infection of B. anthracis which comprises a mixture of an anthrax recombinant fusion protein comprising a EFn protein and a native or mutated or mature PA optionally with a linker, and a truncated anthrax recombinant protein preferably LFn, optionally with one or more suitable adjuvant(s).
It is a further objective of the present invention to provide a composition comprising anthrax recombinant fusion protein along with EFn protein and/or LFn protein.
It is a further objective of the present invention to provide a composition comprising anthrax recombinant fusion protein along with a recombinant fusion protein comprising EFn protein and LFn protein optionally with one or more other linker(s).
It is a further objective of the present invention to provide an immunogenic composition comprising anthrax recombinant fusion proteins comprising truncated Edema factor protein (SEQ. ID No. 2), and protective antigen optionally with a linker wherein linker is truncated lethal factor protein (SEQ. ID No. 1)
It is a further objective of the present invention to provide an immunogenic composition comprising anthrax recombinant fusion proteins comprising truncated Edema factor protein (SEQ. ID No. 2), lethal factor protein (SEQ. ID No. 1) and protective antigen optionally with a linker.
' 5
It is a still further objective of the present invention to provide an immunogenic composition comprising anthrax recombinant fusion protein selected from amino acid sequence set forth in SEQ ID No. 3 or SEQ ID No. 4 or SEQ ID No. 5 optionally with one or more pharmaceutically acceptable adjuvants 10
It is further an objective of the present invention to provide a pre-exposure and post-exposure prophylactic and/or therapeutic composition useful against an infection of B. anthracis in a subject which comprises administration of an effective amount of an anthrax recombinant fusion protein comprising a EFn protein and a native or mutated or mature PA optionally 15 with a truncated anthrax recombinant protein preferably LFn, and optionally one or more adjuvant(s) to the said subject.
It is another objective of the present invention to provide a method to produce an immunogenic prophylactic or therapeutic response against an infection of B. anthracis in a 0 subject which comprises administration of an effective amount of an anthrax recombinant fusion protein comprising a EFn protein, a native or mutated or mature PA and a linker which is LFn protein and/or one or more amino acid residues, and optionally one or more adjuvant(s) to the said subject. 5 It is a further objective of a present invention to provide a DNA construct comprising an expression vector and a DNA fragment comprising nucleic acids encoding the anthrax recombinant fusion protein such that the expression vector when incorporated into a suitable host allows expression of an anthrax recombinant fusion protein. 0 It is further an objective of the present invention to provide nucleic acids encoding the DNA construct.
It is also an objective of the present invention to provide plasmids and primers and the nucleic acids encoding them which are useful in making the DNA construct for the 5 expression of the anthrax recombinant fusion protein.
It is a further objective of a present invention to provide an immunogenic composition or vaccine composition which is potentially immunogenic and safe. Particularly the compositions are useful as a prophylactic and/or a therapeutic vaccine against anthrax. 0 The present invention thus provides a method of producing an immunogenic prophylactic or
therapeutic response against an infection of B. anthracis in a mammal comprising the step of administering to a mammal the immunogenic composition of the present invention described herewith.
BRIEF DESCRIPTION OF FIGURES
Figure-1 Schematic representation of expression system
Figure-2 Schematic representation of recombinant expression plasmid "pPAK- NATPRO"
Figure-3 shows a codon optimized Sequence of PA. Figure-4 shows a Protein Sequence of PA.
Figure-5 shows a LFn with Glycine as linker Recombinant Construct in pET28a, wherein clone LFn has been constructed for the expression of LFn in E.coli BL21(DE3). The genes were amplified from the pXOl region of the B. anthracis using specific primers and inserted in pET-28a expression vector having Kanamycin as selection marker. The recombinant plasmid was then transformed into E.coli BL21 (DE3) cells for the expression of protein.
Figure-6 shows a Nucleotide Sequence of truncated LF.
Figure 7 shows a Protein Sequence of truncated LF (SEQ. ID No. 1).
Figure-8 SDS-PAGE analysis of rLFn expression Figure-9 shows an EFn Recombinant Construct in pET28a, wherein clone EFn has been constructed for the expression of LFn in E.coli BL21(DE3). The genes were amplified from the pXO 1 region of the B. anthracis using specific primers and inserted in pET-28a expression vector having Kanamycin as selection marker. The recombinant plasmid was then transformed into E.coli BL21 (DE3) cells for the expression of protein
Figure-10 shows a Nucleotide Sequence of truncated EF.
Figure-11 shows a Protein Sequence of truncated EF (SEQ. ID No. 2)
Figure- 12 SDS-PAGE analysis of rEFn expression
Figure- 13 shows an EFn+PA with LFn as linker Fusion Construct in pET28a, wherein recombinant fusion construct of EFn+PA fusion protein has been developed using LFn as the linker gene. The genes were amplified from the pXOl region of the B. anthracis using specific primers and inserted in pET-28a expression vector having Kanamycin as selection marker. The recombinant plasmid was then transformed into E.coli BL21 (DE3) cells for the expression of fusion protein. Figure- 14 shows an EFn+PA with LFn as linker Fusion Construct (SEQ. ID No. 3)
Figure- 15 shows the Primers for EFn, LFn and PA in Recombinant Construct EFn+PA with LFn as linker in pET28a.
Figure- 16 shows an EFn+PA with LFn and Glycine as linker Fusion Construct in pET28a, wherein recombinant fusion construct of EFn+PA fusion protein has been
developed using LFn and poly-glycine gene as linkers. The EFn, PA and LFn genes were amplified from the pXOl region of the B. anthracis using specific primers. Primers were designed to insert the polyglycine residues between each gene. pET-28a expression vector with Kanamycin as selection marker was used for cloning of the fusion protein. Transformation was done in E.coli BL21 (DE3) cells for the expression of fusion protein.
Figure- 17 shows an EFn+PA with LFn and Glycine as linker Fusion Construct (SEQ. ID No. 4)
Figure- 18 shows the Primers for EFn+PA with LFn and Glycine as linker Fusion Construct.
Figure- 19 shows an EFn+PA with Glycine as linker Fusion Construct in pET28a, wherein recombinant fusion construct of EFn+PA fusion protein has been developed. The gene for EFn and PA was amplified from pXOl plasmid of B. anthracis using specific primers and was inserted in pET-28a expression vector having Kanamycin as selection marker. The recombinant plasmid was then transformed into E.coli BL21 (DE3) cells for the expression of fusion protein.
Figure-20 shows an EFn+PA with Glycine as linker Fusion Construct (SEQ. ID No. 5).
DETAILED DESCRIPTION OF THE INVENTION The present invention provides anthrax recombinant fusion proteins and nucleic acids encoding the anthrax recombinant fusion proteins. Particularly the present invention provides anthrax recombinant fusion proteins comprising a native or mutated or truncated Edema factor protein preferably a truncated Edema factor protein and a native or mutated or mature Protective Antigen optionally with a linker.
In an embodiment, the present invention provides an anthrax recombinant fusion protein comprising a native or mutated or truncated EF protein preferably a EFn, a native or mutated or truncated LF protein preferably a truncated Lethal factor protein and a native or mutated or mature PA wherein the LFn acts as a linker optionally with one or more other linker(s) such as one or more amino acid residues. In an embodiment, the anthrax recombinant fusion protein or a combination of such fusion protein preferably with a truncated anthrax recombinant protein can result in faster immune responses by targeting all three toxin proteins.
In an aspect of the present invention, the terms PA (Protective Antigen), LF (Lethal Factor) and EF (Edema Factor) shall refer to proteins which are wild types or which are recombinant types or both unless otherwise specifically stated.
In an embodiment, the present invention provides an immunogenic composition against an infection of B. anthracis which comprises a mixture of an anthrax recombinant fusion protein
comprising EFn protein and a native or mutated or mature PA optionally with a linker, and a truncated anthrax recombinant protein preferably LFn, optionally with one or more suitable adjuvant(s). In another embodiment, the present invention provides a pre-exposure and postexposure prophylactic and/or a therapeutic composition useful against an infection of B. anthracis in a subject which comprises administration of an effective amount of an anthrax recombinant fusion protein comprising EFn protein and a native or mutated or mature PA optionally with a truncated anthrax recombinant protein preferably LFn, and optionally one or more adjuvant(s) to the said subject.
In another embodiment, the present invention also provides a DNA construct comprising an expression vector and a DNA fragment comprising nucleic acids encoding the anthrax recombinant fusion protein such that the expression vector when incorporated into a suitable host allows expression of an anthrax recombinant fusion protein. In another embodiment is provided a vaccine composition which is potentially immunogenic and safe. Particularly the compositions are useful as a pre-exposure and post-exposure prophylactic and/or a therapeutic vaccine against anthrax.
In a preferred embodiment of the present invention, the anthrax recombinant fusion protein comprises EFn and a mature Protective Antigen optionally with a linker.
A mature PA also referred to as PA83 is one wherein there is a cleavage of 29 amino acid residues signal sequence from the native PA. In this state, the PA is inactive except for its binding affinity for a receptor. Only after the furin-mediated cleavage to form PA63, the binding of one of the other toxin components is possible. Heptamerization and pore formation after acidification leads to a structure similar to the staphylococcal alpha- hemolysin. Use of a mutated PA also prevents the binding of the Edema factor protein or Lethal factor protein and thus might avoid the formation of Edema Toxin or Lethal Toxin respectively leading to better product safety.
In an embodiment, the composition of the present invention comprising anthrax recombinant fusion protein is capable of producing at least one or more of the anti-PA and anti-EF antibodies that shall work as neutralizing molecules and, therefore, shall interrupt binding activities of the anthrax toxin. Furthermore, since the LF and the EF protein share high N-terminal amino acid homology, some of the antibodies raised against the N-terminal of EF will also react with LF. Therefore, the present invention, by using EFn and native or mutated or mature PA as antigens, may result in faster immune responses by targeting all three toxin proteins since the presence of different antibodies allows attack of different proteins at the same time. Further, in post-exposure anthrax, EFn and LFn provides competitive binding to wild type EF and LF and hence provides more therapeutic protection.
The action of the vaccine of the present invention will be more effective in the post exposure therapeutic cases, as the EFn protein given during the vaccination process will also compete with natural EF or LF for the binding with the site of natural/wild type PA associated with the bacterial infection. The wild type PA when bound to the EFn will not produce any toxic effect and thus help in providing a potent therapeutic product against the bioterrorist attack or accidental spread of Anthrax spores.
In an embodiment of the present invention, an anthrax recombinant fusion protein comprising EFn protein and a native or mutated or mature PA optionally with a linker is provided to target all three proteins i.e., PA, LF, and EF. Many of the antibodies produced against EFn or LFn may neutralize the toxic effect of the anthrax toxin by interrupting the binding of EF and/or LF with PA.
In another embodiment, the present invention provides an anthrax recombinant fusion protein comprising a native or truncated EF protein, a native or truncated LF protein and a native or mutated or mature PA optionally with one or more linkers inserted at one or more sites of the fusion protein chain.
In another embodiment of the present invention, the linker is selected from a group comprising a Lethal factor (LF), a region of LF and amino acids such as glycine, polyglycine or combinations thereof or amino acid residues. Alternatively the linker is also herein referred to as a spacer peptide.
In another embodiment, the present invention provides an anthrax recombinant fusion protein comprising truncated Edema factor protein (SEQ. ID No. 2) and protective antigen optionally with linker wherein linker is truncated lethal factor protein (SEQ. ID No. 1)
In another embodiment, the present invention provides an anthrax recombinant fusion protein comprising truncated Edema factor protein (SEQ. ID No. 2), truncated lethal factor protein (SEQ. ID No. 1) and protective antigen optionally with a linker.
In another embodiment, the present invention provides an anthrax recombinant fusion protein comprising truncated Edema factor protein (SEQ. ID No. 2) and protective antigen optionally with linker wherein linker is amino acid or amino acid residue such as glycine.
In another embodiment, the present invention provides an immunogenic composition comprising anthrax recombinant fusion protein comprising truncated Edema factor protein (SEQ. ID No. 2) and protective antigen optionally with linker wherein linker is
truncated lethal factor protein (SEQ. ID No. 1).
In another embodiment, the present invention provides an immunogenic composition comprising anthrax recombinant fusion protein (SEQ. ID. No. 3)
In another embodiment, the present invention provides an immunogenic composition comprising anthrax recombinant fusion protein comprising truncated Edema factor protein (SEQ. ID No. 2), truncated lethal factor protein (SEQ. ID No. 1) and protective antigen optionally with a linker.
In another embodiment, the present invention provides an immunogenic composition comprising anthrax recombinant fusion protein (SEQ. ID. No. 4)
In another embodiment, the present invention provides an immunogenic composition comprising anthrax recombinant fusion protein comprising truncated Edema factor protein (SEQ. ID No. 2) and protective antigen optionally with linker wherein linker is amino acid or amino acid residue such as glycine.
In another embodiment, the present invention provides an immunogenic composition comprising anthrax recombinant fusion protein (SEQ. ID. No. 5)
In an embodiment, the present invention provides an anthrax recombinant fusion protein that eases the vaccine production by reducing the need for at least three separate production lines for fermentation and purification procedures for each protein i.e. PA, EFn and LFn individually. By making a fusion protein, the same effect is achieved in a single production line. Alternatively, by making a fusion protein comprising EFn protein and a native or mutated or mature PA and making a truncated anthrax recombinant protein preferably LFn requires two production lines for fermentation and purification procedures. Both the EFn-PA fusion protein and the LFn protein can then be mixed in order to obtain the desired vaccine composition of present invention.
In a preferred embodiment, the anthrax recombinant fusion proteins of the present invention are designed in a particular sequence so as to produce a high yield of the proteins. The anthrax recombinant fusion proteins comprise of sequence comprising EFn linked with native or mutated or mature PA by the linker LFn, wherein the EFn and the LFn, and LFn and the native or mutated or mature PA are linked with glycine residue(s). The said particular sequence is surprisingly found to be highly expressive thus leading to a high yield. Alternatively, the said particular sequence of the anthrax proteins improves the immunogenic and/or therapeutic properties and/or the safety profile of the vaccine made by using the novel fusion proteins of the present invention.
In another embodiment of the present invention, at least two antigenic B. anthracis proteins are expressed as a fusion protein, in an E. coli host cell such as the BL- 21(DE3) (from Novagen). The expressed proteins are produced by an optimized fermentation method and purified by one or more techniques known to the art such as column chromatography. The purified proteins are useful in formulating an immunogenic composition, which is again useful as a vaccine against infections caused by B. anthracis. Development of an E. coli BL-21(DE3) expression system involves the development of expression vector (plasmids) to express the target recombinant fusion proteins in an E. coli BL-21(DE3). It might however be understood that alternative vectors/plasmids and/or expression host might be utilized for the production of the novel fusion proteins of the present invention such as the use of Bacillus subtilis as the host cell for the fusion protein expression.
In another embodiment of the present invention, the expression vector described herein is for use in a prokaryotic system; the vector also can contain elements required for replication in either a prokaryotic or eukaryotic host system or both, as desired. Such vectors, which include plasmid vectors and viral vectors such as bacteriophage, baculovirus, retrovirus, lentivirus, adenovirus, vaccinia virus, semliki forest virus and adeno-associated virus vectors, are well known and can be purchased from a commercial source (Promega, Madison Wis.; Stratagene, La Jolla Calif.; GIBCO/BRL, Gaithersburg Md.) or can be constructed by one skilled in the art. The following vectors are provided by way of example; Bacterial: pQE70, pQE30, pET28a (Qiagen), pBluescript SK, pBluescript KS (Stratagene); pTRC99a, pRlT2T (Pharmacia); Eukaryotic: pWLNEO, pXTI, pSG (Stratagene) pSVK3, pSVLSV40 (Pharmacia). Any. other plasmid or vector may be used as long as they are replicable and viable in the host being used to express the fusion proteins of the present invention.
In another embodiment of the present invention is provided a process for preparation of anthrax recombinant fusion proteins. In a further embodiment of the present invention, the process for preparation of anthrax recombinant fusion proteins comprises the following steps:
1. Development of a suitable DNA construct comprising a vector and DNA fragment encoding for the desired fusion protein, 2. Clone development for the production of recombinant fusion protein for example EFn-PA or EFn-(Linker)-PA or EFn-(Linker)-LFn-(Linker)-PA or the like,
3. Expression of the fusion protein in a suitable host,, purification and characterization of recombinant fusion protein,
4. Optionally mixing a truncated anthrax recombinant protein such as LFn with the fusion protein obtained in step (3),
5. Optionally mixing these fusion proteins and adding one or more suitable
adjuvant(s) to step (3) or step (4).
In another embodiment of the present invention, the process for preparation of an anthrax recombinant fusion protein comprises the following steps: 1. Amplification of the PA and EFn and optionally LFn gerie from the genomic DNA of Bacillus antharacis using specific primers optionally having glycine residues as linker,
2. Insertion of fusion protein of PA and EFn and optionally LFn protein in the expression vector, 3. Restriction digestion of the gene and vector,
4. Ligation and transformation into competent E.coli DH5α cells,
5. Selecting the transform ants on LB agar containing an antibiotic such as kanamycin,
6. Screening of the colonies on the agar plates by colony PCR for the presence of the desired gene, 7. Confirming the selected clone by digestion with restriction enzymes, and
8. Transforming the recombinant plasmid into host cells for the expression of the fusion protein.
In an aspect of the present invention, the method used for the preparation of fusion proteins is selected from one of more methods known to the art.
In an embodiment of the present invention, the upstream process for an anthrax recombinant fusion protein production may be carried out by a batch process or preferably by using fed-batch culture technique to improve the yield of the fusion protein. The optimization of various fermentation parameters using fed-batch conditions shall improve protein yields and stability. Standardization of fermentation parameters shall require systematic design of experiments as follows: a) Different nitrogen source such as Soya peptone, yeast extract, yeast autolysate, corn steep liquor or the like or mixtures thereof in the fermentation media. b) Different carbon sources such as glucose, glycerol, galactose, maltose, fructose, lactose or the like or mixtures thereof in the fermentation media. c) Different concentration of inducers such as IPTG, amino acid, sugars or the like or mixtures thereof by auto induction method, and pH of induction process for the expression of recombinant fusion proteins. d) Different induction time such as Low OD, Mid and high OD based upon the growth profile and duration. e) Different induction duration, temperature, various stabilizers and other in-process control method(s) or combination thereof for the stability of the fusion protein. f) Different quantities of carbon and nitrogen sources at pre & post induction phases.
g) Various feeding strategies on the basis of DO-Stat, pH-Stat and Gluco-Stat to achieve high cell density in fed batch fermentation process and to maximize yield of fusion protein.
In an embodiment, the fermentation media used in the present invention is devoid of any component obtained from an animal source.
In an embodiment of the present invention, the downstream purification process of the recombinant fusion proteins is based upon their localization in the cell as inclusion bodies, periplasmic fluid or extracellular secretions. Based on the nature of protein localization and its isoelectric point (PI), various chromatographic methods may be used such as anion exchange chromatography, hydrophobic interaction chromatography and size exclusion or gel filtration chromatography, difiltration or the like, or combinations thereof.
In an embodiment of the present invention, an anthrax recombinant fusion protein shall work as neutralizing molecules and, therefore, will interrupt binding activities of the anthrax toxins with each other. PA is a 735-amino acid polypeptide of about 83 kDa that binds to the surface of mammalian cells by cellular receptors. Once bound, PA is activated by proteolytic cleavage by cellular proteases to a 63-kDa and 20-kDa molecule. 20 kDa is released in the blood and 63-kDa molecule is capable of forming a ring-shaped heptamer in the plasma membrane of the targeted cell exposing PA binding sites for the N-terminal region of either LF or EF which are then internalized by endocytosis. The complex is then carried to an acidic compartment, where the low pH causes a conformational change in the PA63 pre-pore that forms a cation-specific channel and allows the EF and LF to enter into the cytosol. This process is known as endosomal acidification. Once in the cytosol, the EF and LF then carry out their respective damage- inducing processes. EF acts as a Ca2+ and calmodulin dependent adenylate cyclase that greatly increases the level of cAMP in the cell. This increase in cAMP upsets water homeostasis, severely throws the intracellular signaling pathways off balance, and impairs macrophage function, allowing the bacteria to further evade the immune system. LF also helps the bacteria evade the immune system through killing macrophages. Once in these cells, LF acts as a Zn2+-dependent endoprotease that snips off the N-terminus of mitogen-activated protein kinase kinases (MAPKK). This inhibits these kinases by not allowing them to efficiently bind to their substrates, which leads to altered signaling pathways and ultimately to apoptosis. Thus, the synergistic effect of these three proteins leads to cellular death through a cascade of events that allow the proteins to enter the cell and disrupt cellular function. PA is the major immunogen in the anthrax vaccines. Antibodies to PA neutralize anthrax toxin by blocking adherence of PA to host cells, binding of LF/EF to PA, or assembly of PA heptamer. LF represents both a prophylactic and therapeutic target because it has been reported to play a vital role at two different
points in anthrax infection. It elicits humoral and cell-mediated immune response and memory. Combination of rPA and EFn components has been found to enhance the anti- EFn antibody titer, in comparison to immunization with EFn alone. LFn also plays a role in eliciting antibody response against anthrax. The N-terminal truncated LF and EF (about 1-255 amino acids) without the catalytic domain completely lack any toxic effect. The use of EFn and LFn serves as a neutralizing molecule for reducing the toxicity caused by wild type EF and LF.
In another embodiment of the present invention is provided an immunogenic composition to prepare a vaccine against an infection of B. anthracis in a subject and includes an effective immunizing amount of a recombinant fusion protein comprising EFn protein and a native PA optionally with a linker.
The vaccine may be administered by conventional routes, e.g. intravenous, subcutaneous, intraperitoneal and mucosal routes. The said vaccine can be administered through jet injection with needle or without needle. Typically, such vaccines are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior to injection may also be prepared. The preparation may also be emulsified, or the peptide encapsulated in liposomes or microcapsules. The active immunogenic ingredients are often mixed with excipients which are pharmaceutically acceptable and compatible with the active components. Suitable excipients are for example, water, saline, dextrose, glycerol, ethanol, sugars or the like and combinations or derivatives thereof. In addition, if desired, the vaccine may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and/or adjuvants which enhance the effectiveness of the vaccine. Examples of adjuvants which may be effective include but are not limited to aluminum hydroxide, aluminium phosphate, calcium phosphate, immunostimulatory sequence (ISS), CpG, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP),, N-acetyl-nor- muramyl-L-alanyl-D-isoglutamine (CGP 1 1637, referred to as nor-MDP), N- acetylmuramyl-L-alanyl-D-isoglutaminyl -L -alanine (1 '-2'-dipalmitoyl-sn-glycero hydroxylphosphoryloxy) ethylamine (CGP 19835 A, referred to as MTP-PE), and RIBI, which contains three components extracted from bacteria, monophosphoryl lipid A, trehalose dimycolate and cell wall skeleton (MPL + TDM + CWS) in a squalene/Tween-80 emulsion, and other adjuvants known to the art or suitable mixtures thereof.
The vaccines of the present invention may be conventionally administered parenterally by injection, for example, either subcutaneously or intramuscularly.
The vaccines are administered in a manner compatible with the dosage formulation, and in such amount as will be prophylactically and/or therapeutically effective. The
quantity to be administered, which is generally in the range of 0.5 micrograms to 500 micrograms of protein per dose, depends on the subject to be treated, capacity of the subject's immune system to synthesize antibodies, and the degree of protection desired. Precise amounts of active ingredient required to be administered may depend on the judgment of the practitioner and may be particular to each subject.
The vaccine may be given in a single dose schedule, or optionally in a multiple .dose schedule. A multiple dose schedule is one in which, a primary course of vaccination may be with 1-12 preferably 1-6 separate doses, followed by other doses given at subsequent time intervals required to maintain and/or reinforce the immune response, for example, at 1 -4 months for a second dose, and if needed, a subsequent dose(s) after several months. The dosage regimen will also at least in part be determined by the need of the individual and be dependent upon the judgment of the practitioner. In addition, the vaccine containing the immunogenic antigen(s) may be administered in conjunction with other immunoregulatory agents, for example, immunoglobulins, as well as antibiotics.
Additional formulations which are suitable for other modes of administration include microcapsules, suppositories and, in some cases, oral formulations or formulations suitable for distribution as aerosols. For suppositories, traditional binders and carriers may include, for example, polyalkylene glycols or triglycerides; such suppositories may be formed from mixtures containing the active ingredient in the range of 0.5 % to 10 %, preferably 1 -2%.
Oral formulations include such normally employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate and the like. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and contain 10%-95% of active ingredient, preferably 25%-70%. In one embodiment the medicament may be administered intranasally (i.n.). An intranasal composition may be administered in droplet form having approximate diameters in the range of 10-5000 pm. Intranasal administration may be achieved by way of applying nasal droplets or via a nasal spray. It is possible that, following intranasal delivery of antibodies, their passage to the lungs may facilitated by a reverse flow of mucosal secretions.
In a different embodiment, the medicament may be delivered in an aerosol formulation. The aerosol formulation may take the form of a powder, suspension or solution. The size of aerosol particles is one factor relevant to the delivery capability of an aerosol. Thus, smaller particles may travel further down the respiratory airway towards the alveoli than would larger particles. In one embodiment, the aerosol particles have a
diameter distribution to facilitate delivery along the entire length of the bronchi, bronchioles, and alveoli. Alternatively, the particle size distribution may be selected to target an articular section of the respiratory airway, for example the alveoli. The aerosol particles may be delivered by way of a nebulizer or nasal spray. In the case of aerosol delivery of the medicament, the particles may have diameters in the approximate range of 0-50 pm, preferably 1-5 pm. The aerosol formulation of the medicament of the present invention may optionally contain a propellant and/or surfactant. By controlling size of droplets which are to be administered to a subject to within the defined range of the present invention, it is possible to avoid/minimise inadvertent antigen delivery to the alveoli and thus avoid alveoli associated pathological problems such as inflammation and fibrotic scarring of the lungs. In another embodiment of the present invention, the fusion proteins or compositions comprising such proteins may be delivered as topical/transdermal formulation e.g. skin delivery patches.
In an embodiment is provided a method to produce an immunogenic prophylactic or therapeutic response against an infection of B. anthracis in a subject which comprises administration of an effective amount of an anthrax recombinant fusion protein comprising EFn protein, a native or mutated or mature PA and a linker which is LFn protein and/or one or more other amino acid residues, and optionally one or more adjuvant(s) to the said subject. A subject, as used herein, is a mammal, particularly domesticated livestock, animals including but not limited to dogs, cats, cows, bulls, steers, pigs, horses, sheep, goats, mules, donkeys, etc and humans. Preferably the subject is a human. A subject can be of any age at which the subject is able to respond to inoculation with the present vaccine by generating an immune response. The immune response so generated can be completely or partially protective against disease, cellular toxicity, debilitation or death caused by infection with B. anthracis. A subject is also one to which a composition comprising the recombinant fusion proteins of the present invention can be administered prophylactically and/or therapeutically.
The following example is offered by way of illustration and is not intended to limit the scope of the invention in any manner whatsoever.
Example- 1:
Clone development and production of recombinant PA Protective antigen (PA) gene has been codon optimized and synthesized for protein product expression in E.coli. Commercial vector pET 26b (+) were used to express PA gene. After restriction digestion of the gene and vector, both were ligated and transformed into TOPlO {E.coli) competent cells. The transformanfs were plated on LB agar containing 50μg/ml kanamycin. The colonies on the plates were screened by colony PCR for the presence of the desired gene. The selected clone was confirmed by restriction mapping and sequencing. The recombinant construct was then transformed
into E.coli BL21 (DE3) cells for the expression of protein. Below fig-1 illustrate the schematic representation of expression system. The expressed protein was confirmed for its size on SDS-PAGE gel and also by western blotting using Anti-PA monoclonal antibody available from US Biologicals.
Example 2:
Recombinant fusion construct EFn-LFn-PA fusion protein was developed using PA, EFn and LFn gene amplified from Bacillus anthracis using specific primers having glycine residues as spacer peptide inserted in pET-28a expression vector which has Kanamycin as selection marker. The recombinant plasmid was then transformed into E.coli BL21 (DE3) cells for the expression of fusion protein.
Example 3: Composition
The immunogenic composition of anthrax recombinant fusion proteins of the present invention can prepared by following process:
• Add aluminium phosphate gel in a sterile bottle.
• Adding required volume of the recombinant fusion proteins along with Tween 80 in the bottle and mix.
• After mixing add required volume of D-mannitol solution and L- Arginine Hydrochloride solution and again mix it.
• To this composition add required volume of 2-Phenoxyethanol and then add required volume of Sodium phosphate buffer solution to make up the volume; shake and store the final formulation.
Claims
1. Anthrax recombinant fusion proteins comprising a native Edema factor protein (EF) or mutated Edema factor protein (EFm) or truncated Edema factor protein (EFn) and a native or mutated or mature Protective Antigen (PA) optionally with a linker.
2. Anthrax recombinant fusion proteins according to claim 1 wherein the linker is selected from the group consisting of a native Lethal factor protein (LF), mutated Lethal factor protein (LFm), truncated Lethal factor protein (LFn), amino acid residues, glycine, polyglycine and combinations thereof.
3. Anthrax recombinant fusion proteins according to claim 1 comprising truncated Edema factor protein (SEQ ID No. 2) and a native or mutated or mature Protective Antigen optionally with a linker wherein the linker is truncated Lethal factor protein (SEQ ID No. 1).
4. Anthrax recombinant fusion proteins according to claim 3 further comprising an amino acid linker wherein the amino acid is glycine.
5. Anthrax recombinant fusion proteins according to claim 1, comprising EFn protein, LFn protein and a native or mutated or mature PA wherein the LFn protein acts as a linker optionally with one or more other linker(s).
6. Anthrax recombinant fusion proteins according to claim 1 comprising truncated Edema factor protein (SEQ ID No. 2), a mature Protective Antigen and truncated
Lethal factor protein (SEQ ID No. 1) optionally with a one or more other linker(s).
7. Anthrax recombinant fusion proteins according to claim 6 comprising truncated anthrax recombinant proteins having faster, pre-exposure and post-exposure prophylactic and therapeutic immune responses targeting all three toxin proteins
PA, EF and LF.
8. Anthrax recombinant fusion proteins according to claim 1, wherein said fusion proteins are prepared by process comprising the steps of: a. Development of a suitable DNA construct comprising a vector and DNA fragment encoding for the desired fusion protein, b. Clone development for the production of recombinant fusion protein for example EFn-PA or EFn-(Linker)-PA or EFn-(Linker)-LFn-(Linker)-PA or the like, c. Expression of the fusion protein in a suitable host, purification and characterization of recombinant fusion protein, d. Optionally mixing a truncated anthrax recombinant protein such as LFn with the fusion protein obtained in step (c).
9. Anthrax recombinant fusion proteins according to claim 1, wherein said fusion proteins are prepared by process comprising the steps of: a. Amplification of the PA and EF and optionally LF gene from the genomic DNA of Bacillus antharacis using specific primers optionally with linker. b. Restriction digestion of the gene and vector, c. Ligation and transformation into competent E.coli DH5α cells, d. Selecting the transformants on LB agar containing an antibiotic such as kanamycin, e. Screening of the colonies on the agar plates by colony PCR for the presence of the desired gene, f. Confirming the selected clone by digestion with restriction enzymes, and g. Transforming the recombinant plasmid into host cells for the expression of the fusion protein.
10. Immunogenic compositions against an infection of B. anthracis comprising anthrax recombinant fusion proteins comprising a native Edema factor protein (EF) or mutated Edema factor protein (EFm) or truncated Edema factor protein (EFn) and a native or mutated or mature Protective Antigen (PA) optionally with a linker and optionally with one or more pharmaceutically acceptable adjuvants.
11. Immunogenic compositions according to claim 10 comprising truncated Edema factor protein (SEQ ID No. 2) and a native or mutated or mature Protective Antigen optionally with a linker wherein the linker is truncated Lethal factor protein (SEQ ID No. 1).
12. Immunogenic compositions according to claim 1 1 comprising truncated Edema factor protein (SEQ ID No. 2), mature Protective Antigen and truncated Lethal factor protein (SEQ ID No. 1) optionally with a linker, wherein the linker is selected from one or more amino acid residues.
13. An immunogenic composition comprising anthrax recombinant fusion proteins . selected from amino acid sequence set forth in SEQ ID No. 3 or SEQ ID No. 4 or
SEQ ID No. 5 optionally with one or more pharmaceutically acceptable adjuvants.
14. Immunogenic composition according to claim 10 wherein adjuvants can be selected from the group comprising aluminum hydroxide, N-acetyl-muramyl-L- threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D- isoglutamine (CGP 1 1637, referred to as nor-MDP), N-acetylmuramyl-L-alanyl- D-isoglutaminyl-L-alanine (l'-2'-dipalmitoyl-sn-glycero hydroxylphosphoryloxy) ethylamine (CGP 19835 A, referred to as MTP-PE), and RIBI, which contains three components extracted from bacteria, monophosphoryl lipid A, trehalose dimycolate and cell wall skeleton (MPL + TDM + CWS) in a squalene/Tween-80 emulsion and mixtures thereof.
15. Immunogenic composition according to claim 14 further comprises auxiliary substances or excipients.
16. Immunogenic composition according to claim 15 wherein auxiliary substance is selected from the group comprising wetting or emulsifying agents, pH buffering agents.
17. Immunogenic composition according to claim 16 wherein excipient is selected from the group comprising water, normal saline, dextrose, glycerol, ethanol and combinations thereof.
18. A method of producing an immunogenic prophylactic or therapeutic response against an infection of B. anthracis in a mammal comprising the step of administering to a mammal the immunogenic composition of claim 10.
19. Anthrax recombinant fusion proteins according to claim 1 wherein a DNA construct comprises an expression vector and a DNA fragment comprising nucleic acids encoding the anthrax recombinant fusion protein such that the expression vector when incorporated into a suitable host allows expression of an anthrax recombinant fusion protein.
20. The anthrax recombinant fusion proteins substantially as herein- described and illustrated by the examples.
21. The process for the preparation of anthrax recombinant fusion proteins substantially as herein described and illustrated by the examples.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1252DE2007 | 2007-06-11 | ||
| IN1252/DEL/2007 | 2007-06-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2008152655A1 true WO2008152655A1 (en) | 2008-12-18 |
Family
ID=40129294
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IN2008/000369 WO2008152655A1 (en) | 2007-06-11 | 2008-06-11 | Anthrax fusion proteins, compositions and uses thereof |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2008152655A1 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5591631A (en) * | 1993-02-12 | 1997-01-07 | The United States Of America As Represented By The Department Of Health And Human Services | Anthrax toxin fusion proteins, nucleic acid encoding same |
| WO2003048390A1 (en) * | 2001-12-05 | 2003-06-12 | Rakesh Bhatnagar | A process for the preparation of a non-toxic anthrax vaccine |
| US20040028695A1 (en) * | 2002-04-12 | 2004-02-12 | Sukjoon Park | Recombinant immunogenic compositions and methods for protecting against lethal infections from Bacillus anthracis |
| WO2008048344A2 (en) * | 2006-02-13 | 2008-04-24 | Fraunhofer Usa, Inc. | Bacillus anthracis antigens, vaccine compositions, and related methods |
-
2008
- 2008-06-11 WO PCT/IN2008/000369 patent/WO2008152655A1/en active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5591631A (en) * | 1993-02-12 | 1997-01-07 | The United States Of America As Represented By The Department Of Health And Human Services | Anthrax toxin fusion proteins, nucleic acid encoding same |
| WO2003048390A1 (en) * | 2001-12-05 | 2003-06-12 | Rakesh Bhatnagar | A process for the preparation of a non-toxic anthrax vaccine |
| US20040028695A1 (en) * | 2002-04-12 | 2004-02-12 | Sukjoon Park | Recombinant immunogenic compositions and methods for protecting against lethal infections from Bacillus anthracis |
| WO2008048344A2 (en) * | 2006-02-13 | 2008-04-24 | Fraunhofer Usa, Inc. | Bacillus anthracis antigens, vaccine compositions, and related methods |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1962890B1 (en) | Immunogenic composition | |
| US8445650B2 (en) | Mutant botulinum neurotoxin serotype A polypeptide and uses thereof | |
| JP5097544B2 (en) | Preparation of protective antigen from Bacillus anthracis | |
| US20150266934A1 (en) | Methods for protection against lethal infection with bacillus anthracis | |
| JP6084631B2 (en) | Clostridium difficile toxin-based vaccine | |
| US7947268B2 (en) | Salmonella based oral vaccines for anthrax | |
| JP2012501959A (en) | Composition comprising Yersinia pestis antigen | |
| US20050112145A1 (en) | Anthrax antigenic compositions | |
| MX2015002485A (en) | Clostridium difficile polypeptides as vaccine. | |
| KR20110091560A (en) | Glutamyl trna synthetase (gts) fragments | |
| KR101130884B1 (en) | Recombinant fusion protein produced by fusing Vibrio vulnificus flagellin and pathogenic antigens and the mucosal vaccine containing the same as an active ingredient | |
| WO2008152654A1 (en) | Anthrax fusion proteins, compositions and uses thereof | |
| CN111249455A (en) | Pseudomonas antigens and antigen combinations | |
| WO2008152655A1 (en) | Anthrax fusion proteins, compositions and uses thereof | |
| US20130149330A1 (en) | Pharmaceutical compositions and methods of blocking bacillus anthracis | |
| JP2019531100A (en) | Vaccine construct and its use against staphylococcal infections | |
| US10293040B1 (en) | Pharmaceutical compositions and methods of blocking Bacillus anthracis | |
| US9233150B2 (en) | Combination vaccine | |
| KR20220133632A (en) | Recombinant protein comprising spike protein S1 of PEDV-derived protein and ferritin-derived protein and use thereof | |
| KR20230004330A (en) | Peptide for enhancing neutralizing antibody-producing ability and vaccine composition comprising the same | |
| US9610341B2 (en) | Bacterial vaccine | |
| KONDAKOVA et al. | Reviews, challenges | |
| AU2002341182A1 (en) | Anthrax antigenic compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08763754 Country of ref document: EP Kind code of ref document: A1 |
|
| DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 08763754 Country of ref document: EP Kind code of ref document: A1 |